Ignite Creation Date:
2024-05-06 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05122182
Status:
TERMINATED
Last Update Posted:
2023-09-15
First Post:
2021-11-14
Brief Title:
Controlled Trial of Angiotensin Receptor Blocker ARB Chemokine Receptor Type 2 CCR2 Antagonist for the Treatment of COVID-19
Sponsor:
University of Sydney
Organization:
University of Sydney
Study Overview
Official Title:
An Investigator Initiated International Multi-Centre Multi-Arm Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker ARB Chemokine Receptor Type 2 CCR2 Antagonist for the Treatment of COVID-19
Status:
TERMINATED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Withdrawal of funding support from the trial funder
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLARITY 2
Brief Summary:
CLARITY 20 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium a CCR2 antagonist and candesartan an ARB in patients hospitalised with COVID-19 disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None